The antitumor effect of IL-2 immunotherapy is probably derived from its ability to promote proliferation, differentiation, and survival of immune cells that include activated T, NK, and B cells in vivo, which consequently induces tumor regression and inhibits tumor growth (6, 78, 79). Here, IL2 is linked to neoplasm.